Pharma Mar, S.A. (PHMMF)

Market Cap	1.66B
Revenue (ttm)	189.96M
Net Income (ttm)	21.48M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	77.42
Forward PE	24.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	66
Open	105.60
Previous Close	80.91
Day's Range	80.91 - 105.60
52-Week Range	31.15 - 105.60
Beta	-0.06
RSI	3.73
Earnings Date	Apr 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR